Skip to content
Contactez-nous: (+33) 1 64 62 10 12
Theradiag
  • Home
  • Company
    • About us
    • Our history
    • A word from our CEO
    • Board of directors
    • Our management team
    • Know-how
    • Privacy policy
  • Theranostic
    • Therapeutic Drug Monitoring of Biologics
      • When to perform TDM ?
      • Results interpretation
      • Therapeutic Thresholds
      • Tracker Publications
      • Guidelines
      • Frequently asked questions
    • TRACKER
      • LISA TRACKER
      • i-Tracker
      • i-Track 10
      • ez-Track 1 & ez-Tracker
      • Immunotrol Tracker
    • Patient Stratification – PredictImmune
    • American Customers
  • Diagnostics
    • Autoimmunity
      • Reagents – Autoimmunity
      • Quality Control – Auto-Immunity
    • Other fields
    • Instrumentation
      • Theralis
      • FIDIS™
  • Services
    • Technical Documentation Download Center
  • News
    • Press Releases
    • List of upcoming events
    • Congress calendar
  • Investors
    • Welcome Message
    • Financial News
      • Register to receive our latest news
      • Press Releases
      • Financial Reports
      • Financial presentations
    • Shareholder information
      • Stock information
      • Shareholding
      • Analyst coverage
      • Letters to shareholders
      • General meeting
    • Regulated information
      • Share capital and voting rights
      • Corporate governance & internal control
      • Statutory auditors fees
      • Description of the buyback program
      • Prospectus
      • Share buyback statement
      • Charters and code of ethics / Anti-corruption
      • Other regulated information
    • Governance
      • Board of directors
      • Our management team
      • Statute and internal regulations
      • Quiet period policy and trading windows
    • Investor contacts and registration
    • Legal notice
  • Contacts
  • Français
  • English
Menu Close

Analyst coverage

  1. Home>
  2. Investors>
  3. Shareholder information>
  4. Analyst coverage

Analysts covering Theradiag :

  • SWISSLIFE BioStrategic Research – Lionel Labourdette
  • PORTZAMPARC – Clement Bassat

You can access the latest research notes published (only available in French) :

THERADIAG Flash Portzamparc 12.01.2021

THERADIAG Flash Portzamparc 12.01.2021

THERADIAG Flash Portzamparc 22.07.2020

THERADIAG Flash SwissLife 22.07.2020

THERADIAG Flash SwissLife 23.04.2020

THERADIAG Flash SwissLife 20.03.2020

THERADIAG Flash Portzamparc 31.01.2020

THERADIAG Flash SwissLife 31.01.2020

THERADIAG Flash SwissLife  11.12.2019

THERADIAG Flash SwissLife 25.09.2019

THERADIAG Flash SwissLife 19.07.2019 

THERADIAG Flash Portzamparc 19.07.2019

THERADIAG Flash Portzamparc 02.04.2019

Latest Press Releases

  • 01/03/2023: Change of Governance
    1 March 2023/
    0 Comments
  • THERADIAG reports 2022 revenue of €12.2 million, up 9.7%
    16 January 2023/
    0 Comments
  • THERADIAG announces its 2023 financial calendar
    6 January 2023/
    0 Comments

Events

01 - 04 Mar 2023

18th Congress of ECCO

Bella Center
15 - 17 Mar 2023

XXIX th CECOS seminar

Best Western Premier Hotel de la Paix
16 - 19 Mar 2023

JFHOD

No event found!
Load More

Next financial Event

No event found!

Useful links

  • Diagnostic
  • Theranostic
  • Events
  • Register to receive our latests news

Contact Information

  • Address:14, Rue Ambroise Croizat, 77183 Croissy Beaubourg, France
  • Phone:+33 1 64 62 10 12
  • Email:info@theradiag.comOpens in your application

Follow Us

Theradiag ©
  • Home
  • Company
    • About us
    • Our history
    • A word from our CEO
    • Board of directors
    • Our management team
    • Know-how
    • Privacy policy
  • Theranostic
    • Therapeutic Drug Monitoring of Biologics
      • When to perform TDM ?
      • Results interpretation
      • Therapeutic Thresholds
      • Tracker Publications
      • Guidelines
      • Frequently asked questions
    • TRACKER
      • LISA TRACKER
      • i-Tracker
      • i-Track 10
      • ez-Track 1 & ez-Tracker
      • Immunotrol Tracker
    • Patient Stratification – PredictImmune
    • American Customers
  • Diagnostics
    • Autoimmunity
      • Reagents – Autoimmunity
      • Quality Control – Auto-Immunity
    • Other fields
    • Instrumentation
      • Theralis
      • FIDIS™
  • Services
    • Technical Documentation Download Center
  • News
    • Press Releases
    • List of upcoming events
    • Congress calendar
  • Investors
    • Welcome Message
    • Financial News
      • Register to receive our latest news
      • Press Releases
      • Financial Reports
      • Financial presentations
    • Shareholder information
      • Stock information
      • Shareholding
      • Analyst coverage
      • Letters to shareholders
      • General meeting
    • Regulated information
      • Share capital and voting rights
      • Corporate governance & internal control
      • Statutory auditors fees
      • Description of the buyback program
      • Prospectus
      • Share buyback statement
      • Charters and code of ethics / Anti-corruption
      • Other regulated information
    • Governance
      • Board of directors
      • Our management team
      • Statute and internal regulations
      • Quiet period policy and trading windows
    • Investor contacts and registration
    • Legal notice
  • Contacts
  • Français
  • English
We use cookies to ensure the best experience on our website. If you continue to use this site, we will assume that you are satisfied.OkNoLearn more